Articles By Estel Grace Masangkay

  1. GSK's Hepatitis C Vaccine Shows Positive Phase 1 Trial Results 11/11/2014

    Oxford University reported that an investigational hepatitis C vaccine has demonstrated positive results in a Phase 1 clinical trial conducted at the University.

  2. FDA Approves Lilly's Cyramza + Paclitaxel For Advanced Gastric Cancer 11/10/2014

    Eli Lilly & Co. announced the U.S. Food and Drug Administration (FDA) granted approval to its drug Cyramza (ramucirumab) in combination with chemotherapy paclitaxel as treatment for advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma, which has become progressive while being treated or after being treated with fluoropyrimidine- or platinum-containing chemotherapy.

  3. Sea Sponge Drug Extends Breast Cancer Survival By 5 Months 11/7/2014

    Cancer Research UK reported that a cancer drug derived from a sea sponge demonstrated potential to extend survival of patients with advanced triple negative breast cancer by an average of five months.

  4. AstraZeneca, Pharmacyclics Ink 2 Oncology Partnerships 11/7/2014

    AstraZeneca and Pharmacyclics announced that they have agreed to enter into multiple clinical trial collaborations to investigate drug combo therapies in solid tumors and several hematological cancers.

  5. Genmab To Transfer Ofatumumab From GSK To Novartis 11/6/2014

    International biotech firm Genmab announced that it has agreed to transfer its ofatumumab collaboration with GlaxoSmithKline to Novartis.

  6. PATH Awarded $156M In Grant For Malaria Vaccine 11/5/2014

    International nonprofit organization PATH announced that it has received a $156 million grant from the Bill & Melinda Gates Foundation to support the PATH Malaria Vaccine Initiative (MVI).

  7. Merck Posts Phase 2B Results Of HIV Drug Doravirine 11/5/2014

    Merck presented results from the 48-week Phase 2B study of its experimental HIV drug doravirine (MK-1439) in patients who have not undergone therapy for their disease.

  8. New Vaccine-Centered Biotech To Target Pneumococcal Disease 11/4/2014

    Affinivax, a biotech firm dedicated to the development of novel vaccines, announced its launch this week with a $4 million investment from the Bill & Melinda Gates Foundation to support the company’s Multiple Antigen Presenting System (MAPS) technology platform.

  9. GPCR Consortium, 3 Pharma Firms To Pool Early Drug Research 11/4/2014

    The GPCR Consortium launched this week in collaboration with three major pharmaceutical firms and partner research institutes to advance the study of a family of proteins that plays a part in many diseases.

  10. Penn's Drug For Rare Blood Disorder Snags FDA Orphan Status 10/31/2014

    Penn Medicine announced that AMY-101, a drug developed at the institute, has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) as treatment for the rare and deadly blood disorder, paroxysmal nocturnal hemoglobinuria (PNH).